CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies

Metastatic castration-resistant prostate cancers (mCRPCs) are treated with therapies that antagonize the androgen receptor (AR). Nearly all patients develop resistance to AR-targeted therapies (ARTs). Our previous work identified CREB5 as an upregulated target gene in human mCRPC that promoted resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Justin H, Arafeh, Rand, Seo, Ji-Heui, Baca, Sylvan C, Ludwig, Megan, Arnoff, Taylor E, Sawyer, Lydia, Richter, Camden, Tape, Sydney, Bergom, Hannah E, McSweeney, Sean, Rennhack, Jonathan P, Klingenberg, Sarah A, Cheung, Alexander TM, Kwon, Jason, So, Jonathan, Kregel, Steven, Van Allen, Eliezer M, Drake, Justin M, Freedman, Matthew L, Hahn, William C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2022
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135408/
https://www.ncbi.nlm.nih.gov/pubmed/35550030
http://dx.doi.org/10.7554/eLife.73223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135408/
https://www.ncbi.nlm.nih.gov/pubmed/35550030
http://dx.doi.org/10.7554/eLife.73223

Ejemplares similares